VERASTEM INC (VSTM) Stock News
NASDAQ:VSTM - Nasdaq - US92337C2035 - Common Stock - Currency: USD
VSTM Latest News, Press Relases and Analysis
Which stocks are experiencing notable movement on Monday?
Intrigued by the market activity in the middle of the day on Monday? Uncover the key winners and losers of today's session in our insightful analysis.
Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building?
TEM's Genomics revenues soar 89% on oncology test gains and Ambry Genetics' boost. New assays could fuel more growth.
Verastem Announces Positive Data From Cancer Trial Conducted By Partner: Retail Turns Bullish
In a study conducted in China, GFH375, also known as VS-7375 in the U.S., showed an overall response rate of 52% in patients with pancreatic ductal adenocarcinoma and 42% in those with non-small cell lung cancer.
VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval
Verastem Oncology jumps 22% on FDA nod for Avmapki Fakzynja, the first approved KRAS-mutant LGSOC therapy, with strong early data in a pancreatic cancer study.
Verastem Oncology to Present at the Jefferies Global Healthcare Conference
Deutsche Bank Reaffirms Buy Rating on Roblox Amid Google Deal
Deutsche Bank reaffirmed its Buy rating on Roblox Corporation (NYSE:RBLX) shares on May 19, with a price target of $78. The report followed the announcement of a new partnership between Roblox and Google for Rewarded Video Ads. With plans to scale distribution even further in the near future, Roblox’s partnership with Google will utilize AdMob […]
Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates
Verastem’s Combination Therapy For Ovarian Cancer Gets FDA Approval: Retail’s Pleased
The combination of Avutometinib capsules and Defactinib tablets, under the brand name Avmapki Fakzynja Co-pack, can now be used to treat patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior treatment.
Verastem Oncology to Present at Upcoming Investor Conferences
Verastem Oncology Announces $75 million Private Placement
Verastem Oncology to Report Q1 Earnings: What's in the Cards?
Devoid of any marketed drugs, investors are set to focus on VSTM's pipeline updates when it reports first-quarter 2025 earnings.
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Wall Street Analysts Believe Verastem (VSTM) Could Rally 100.94%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 100.9% in Verastem (VSTM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025
Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates
Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer
Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference
Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers
Verastem Oncology Names Matthew E. Ros as Chief Operating Officer
